A Molecular Diagnostics Company
Making Early Cancer Detection the New Standard of Primary Care
Our Mission
For heart disease, thyroid function and diabetes… frequent, recurrent, sequential monitoring and screening are standard of primary care in asymptomatic populations.
Our Science
Find out how we’re unlocking frequent, recurring monitoring for early cancer signal as the new standard of primary care.
More accurate & reliable
More cost effective
fully scalable
significant societal impact
Our Social Impact
Latest News
AcuamarkDx Welcomes Two New Board Members
December 5, 2024
AcuamarkDx is pleased to announce the addition of Tim Gordon and Chiara Gabbi, MD, PhD, to ourboard of directors. Their expertise in financial strategy and clinical research will help guide us as we advance our groundbreaking early cancer detection technology through clinical development and toward commercialization.
Acuamark at LSI Europe 2024
November 5, 2024
AcuamarkDx's Co-Founder and CEO Bernard Peperstraete recently presented to a full room at #LSIEurope24.
Bernard highlighted Acuamark's groundbreaking advancements in early cancer detection technology and shared insights into our innovative approach— including proprietary qPCR and machine learning-driven assays, which achieve high sensitivity and specificity in detecting early-stage cancer.
Watch the presentation here:
Acuamark on LinkedIn
October 10, 2024
AcuamarkDx's Co-Founder and CEO Bernard Peperstraete will be attending HLTH 2024 in Las Vegas later this month.
If you're interested in learning more about AcuamarkDx’sqPCR diagnostics technology for cancer screening + recurrence monitoring, please reach out to schedule a meeting with Bernard.
We hope to see you at the event!
bit.ly/4eBz17Z
